Preliminary In Vitro and In Vivo Insights of In Silico Candidate Repurposed Drugs for Alzheimer’s Disease

Author:

Savva Kyriaki1,Zachariou Margarita1ORCID,Kynigopoulos Demos2ORCID,Fella Eleni2,Vitali Maria-Ioanna3,Kosofidou Xeni3,Spyrou Michail3ORCID,Sargiannidou Irene4ORCID,Panayiotou Elena2,Dietis Nikolas3ORCID,Spyrou George M.1ORCID

Affiliation:

1. Bioinformatics Department, The Cyprus Institute of Neurology and Genetics, 2371 Nicosia, Cyprus

2. Department of Neuropathology, The Cyprus Institute of Neurology and Genetics, 2371 Nicosia, Cyprus

3. Experimental Pharmacology Laboratory, Medical School, University of Cyprus, 2109 Nicosia, Cyprus

4. Neuroscience Department, The Cyprus Institute of Neurology and Genetics, 2371 Nicosia, Cyprus

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disease and is the most common type of dementia. Although a considerably large amount of money has been invested in drug development for AD, no disease modifying treatment has been detected so far. In our previous work, we developed a computational method to highlight stage-specific candidate repurposed drugs against AD. In this study, we tested the effect of the top 13 candidate repurposed drugs that we proposed in our previous work in a severity stage-specific manner using an in vitro BACE1 assay and the effect of a top-ranked drug from the list of our previous work, tetrabenazine (TBZ), in the 5XFAD as an AD mouse model. From our in vitro screening, we detected 2 compounds (clomiphene citrate and Pik-90) that showed statistically significant inhibition against the activity of the BACE1 enzyme. The administration of TBZ at the selected dose and therapeutic regimen in 5XFAD in male and female mice showed no significant effect in behavioral tests using the Y-maze and the ELISA immunoassay of Aβ40. To our knowledge, this is the first time the drug tetrabenazine has been tested in the 5XFAD mouse model of AD in a sex-stratified manner. Our results highlight 2 drugs (clomiphene citrate and Pik-90) from our previous computational work for further investigation.

Funder

Muscular Dystrophy Association Cyprus/Telethon Cyprus

Publisher

MDPI AG

Subject

Paleontology,Space and Planetary Science,General Biochemistry, Genetics and Molecular Biology,Ecology, Evolution, Behavior and Systematics

Reference41 articles.

1. Alzheimer’s disease hypothesis and related therapies;Du;Transl. Neurodegener.,2018

2. Lecanemab in Early Alzheimer’s Disease;Swanson;N. Engl. J. Med.,2023

3. Hamada, Y., and Kiso, Y. (2017). Quantitative Structure-Activity Relationship, IntechOpen.

4. Phenotypic and Biochemical Analyses of BACE1- and BACE2-deficient Mice;Dominguez;J. Biol. Chem.,2005

5. BACE1 Gene Deletion Prevents Neuron Loss and Memory Deficits in 5XFAD APP/PS1 Transgenic Mice;Ohno;Neurobiol. Dis.,2007

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3